Back to Authors

Gehrking, Tonette L.

A5090369855 | I1330342723

Mayo Clinic

Mayo Clinic

Citations 28

Autonomic Function Testing – Normative Values in Children and Adolescents (S33.005)

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217893

Glial Fibrillary Acidic Protein in Multiple System Atrophy (P10-7.003)

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217890

White Matter Abnormalities Track Disease Progression in Multiple System Atrophy

Movement Disorders Clinical Practice | June 24, 2024 | Volume: 11 | Issue: 9 | Pages: 1085-1094

10.1002/mdc3.14147 | PMID 38923361

Abstract Background White matter (WM) abnormalities have been implicated in clinically relevant functional decline in multiple system atrophy (MSA). Objective To identify the WM and gray matter (GM) abnormalities in MSA and assess the utility of longitudinal structural and diffusion changes as surrogate markers for tracking disease progression in MSA. Methods Twenty‐seven participants with early MSA [15 with clinically predominant cerebellar (MSA‐C) and 12 with clinically predominant parkinsonian features (MSA‐P)] and 14 controls were enrolled as a part of our prospective, longitudinal study of synucleinopathies. Using structural magnetic resonance imaging (MRI) and diffusion MRI (diffusion tensor and neurite orientation and dispersion density imaging), we analyzed whole and regional brain changes in these participants. We also evaluated temporal imaging trajectories based on up to three annual follow‐up scans and assessed the impact of baseline diagnosis on these imaging biomarkers using mixed‐effect models. Results MSA patients exhibited more widespread WM changes than GM, particularly in the cerebellum and brainstem, with greater severity in MSA‐C. Structural and diffusion measures in the cerebellum WM and brainstem deteriorated with disease progression. Rates of progression of these abnormalities were similar in both MSA subtypes, reflecting increasing overlap of clinical features over time. Conclusion WM abnormalities are core features of MSA disease progression and advance at similar rates in clinical MSA subtypes. Multimodal MRI imaging reveals novel insights into the distribution and pattern of brain abnormalities and their progression in MSA. Selected structural and diffusion measures may be useful for tracking disease progression in MSA clinical trials.
Mapping White Matter Changes to Monitor Disease Progression in Multiple System Atrophy (P5-3.008)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206227

Neurofilament Light Chain in CSF and Plasma in Multiple System Atrophy – A Prospective, Longitudinal Biomarker Study (S9.003)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205330

Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy Results in Growth Factor Spike (S12.002)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s12.002

Comparison of Baroreflex Sensitivity to Fall and Rise in Blood Pressure Induced by the Valsalva Maneuver (S36.007)

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s36.007

Randomized Trial of Rifampicin in MSA: Effect on Autonomic Function (S16.006)

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s16.006

Determinants of Vagal Baroreflex Sensitivity and Normative Data (P1.096)

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p1.096

Long-term Administration of Intrathecal Mesenchymal Stem Cells in Multiple System Atrophy – A Compassionate Use Experience (S18.004)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s18.004